The early onset of menopause is a known risk factor for primary open angle glaucoma (POAG) with the associated hormonal changes seeming to play an important role. This begged the question of whether postmenopausal hormone therapy could actually play a role in reducing the risk of glaucoma and act in a protective fashion.

Research on Glaucoma Risk & Postmenopausal Hormones

According to researchers publishing in JAMA Ophthalmology taking estrogen only postmenopausal hormone (PMH) treatment may help reduce the risk for primary open-angle glaucoma (POAG). By reviewing data from 152,163 women 50 years or older the researchers found that 1.9 percent of enrollees developed POAG. Each additional month of use of PMH containing estrogen only was associated with a 0.4 percent reduced risk for POAG whereas each additional month of use of estrogen + progesterone or estrogen + androgen hormones did not affect risk for POAG. This is interesting information and will require further clinical studies to understand fully but may offer some novel treatments for primary open angle glaucoma (POAG), an insidious sight threatening eye diseases and the most common type of glaucoma.

If you or someone you know has questions about glaucoma, glaucoma risk factors and the role of postmenopausal hormone therapy in glaucoma risk, or needs to schedule an appointment, please call The Eye Clinic of Texas, an affiliate of Houston Eye Associates, at 800-423-3937, visit The Eye Clinic of Texas or facebook.com/ecot.lasik. The Eye Clinic of Texas is an affiliate of Houston Eye Associates, the largest ophthalmology clinic in the nation. We are a leading eye care practice serving the greater Houston, Galveston, League City and Texas City with offices at 1100 Gulf Freeway, Suite 114, League City, Texas 77573, 7111 Medical Center Drive, Suite 110, Texas City, Texas 77590 and 2302 Avenue P, Galveston, Texas.


Comments are closed.